{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:16:50Z","timestamp":1790907410807,"version":"4.1.0"},"reference-count":255,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation \u2013 Flanders","doi-asserted-by":"crossref","award":["1SHDM24N"],"award-info":[{"award-number":["1SHDM24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01189-7","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:41:52Z","timestamp":1769006512000},"page":"63-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What\u2019s the Current Status?"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-7334","authenticated-orcid":false,"given":"Finn","family":"Segers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-2291","authenticated-orcid":false,"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"9","key":"1189_CR1","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol."},{"issue":"1","key":"1189_CR2","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","volume":"14","author":"DT Zhu","year":"2024","unstructured":"Zhu DT, Lai PA, Zhang L, Attar H, Rebbeck TR. Multiple myeloma incidence and mortality trends in the United States, 1999\u20132020. Sci Rep. 2024;14(1):14564.","journal-title":"Sci Rep"},{"issue":"9","key":"1189_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1189_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"11","key":"1189_CR5","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.4049\/jimmunol.1202860","volume":"190","author":"A Franco","year":"2013","unstructured":"Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190(11):5739\u201346.","journal-title":"J Immunol"},{"issue":"Suppl. 1","key":"1189_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Suppl. 1):157.","journal-title":"Blood"},{"key":"1189_CR7","doi-asserted-by":"crossref","unstructured":"Cohen AD, Trudel S, Forsberg P, Fonseca R, Krishnan A, Spencer A, et al. GO39775: a multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5\/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2020;38(15_Suppl.):TPS8551.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8551"},{"issue":"Suppl. 1","key":"1189_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"J Richter","year":"2024","unstructured":"Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S, et al. Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood. 2024;144(Suppl. 1):1021.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1189_CR9","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1182\/blood-2024-199519","volume":"144","author":"M Delforge","year":"2024","unstructured":"Delforge M, Richter J, Cohen YC, Corradini P, Sborov DW, Lesokhin AM, et al. Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received \u22651 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): results from the phase I\/II CAMMA 2 study. Blood. 2024;144(Suppl. 1):4732.","journal-title":"Blood"},{"key":"1189_CR10","doi-asserted-by":"crossref","unstructured":"Kumar S, Bachier CR, Cavo M, Corradini P, Delforge M, Janowski W, et al. CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. J Clin Oncol. 2023;41(16_Suppl.):TPS8064.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064"},{"issue":"4","key":"1189_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1369\/00221554221079579","volume":"70","author":"M Marella","year":"2022","unstructured":"Marella M, Yao X, Carreira V, Bustamante MF, Clark HB, Jackson CC, et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy. J Histochem Cytochem. 2022;70(4):273\u201387.","journal-title":"J Histochem Cytochem"},{"issue":"12","key":"1189_CR12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099\u2013103.","journal-title":"Nat Med"},{"issue":"3","key":"1189_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cei\/uxae043","volume":"217","author":"P Guo","year":"2024","unstructured":"Guo P, Wang Y, He H, Chen D, Liu J, Qiang W, et al. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Clin Exp Immunol. 2024;217(3):221\u201332.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1189_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785\u201395.","journal-title":"Haematologica"},{"issue":"20","key":"1189_CR15","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128\u201338.","journal-title":"Blood"},{"issue":"10","key":"1189_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R de Montes Oca","year":"2021","unstructured":"de Montes Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1189_CR17","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1002\/ajh.26823","volume":"98","author":"IV Kostopoulos","year":"2023","unstructured":"Kostopoulos IV, Kakalis A, Birmpilis A, Angelis N, Orologas-Stavrou N, Rousakis P, et al. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients. Am J Hematol. 2023;98(3):E65\u20137.","journal-title":"Am J Hematol"},{"issue":"12","key":"1189_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641\u201353.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1189_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1189_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.","journal-title":"Blood Cancer J"},{"issue":"22","key":"1189_CR21","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198\u2013212.","journal-title":"Cancer"},{"issue":"10","key":"1189_CR22","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312.","journal-title":"Lancet Haematol."},{"key":"1189_CR23","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/S2152-2650(24)02297-3","volume":"24","author":"VTM Hungria","year":"2024","unstructured":"Hungria VTM, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. P-395 updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24:S261\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1189_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01212-0","volume":"15","author":"P Mukhopadhyay","year":"2025","unstructured":"Mukhopadhyay P, Abdullah HA, Opalinska JB, Paka P, Richards E, Weisel K, et al. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 2025;15(1):15.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1189_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407.","journal-title":"N Engl J Med"},{"issue":"8","key":"1189_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(8):1067\u201380.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1189_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"key":"1189_CR28","doi-asserted-by":"crossref","unstructured":"Dimopolous MA, Beksac M, Pour L, Delimapsi S, Vorobyev V, Quach H, et al. MM-1045: updated results from the phase 3 DREAMM-8 Study of belantamab mafodotin (Belamaf) plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2025;25:S959\u201360.","DOI":"10.1016\/S2152-2650(25)02675-8"},{"issue":"1","key":"1189_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","volume":"200","author":"T Shragai","year":"2023","unstructured":"Shragai T, Magen H, Lavi N, Gatt M, Trestman S, Zektser M, et al. Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023;200(1):45\u201353.","journal-title":"Br J Haematol"},{"key":"1189_CR30","doi-asserted-by":"crossref","unstructured":"de la Rubia J, Alonso R, Clavero ME, Askari E, Garcia A, Anton C, et al. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain. Cancers (Basel). 2023","DOI":"10.3390\/cancers15112964"},{"issue":"10","key":"1189_CR31","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3324\/haematol.2022.281772","volume":"108","author":"A Talbot","year":"2023","unstructured":"Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, et al. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study. Haematologica. 2023;108(10):2774\u201382.","journal-title":"Haematologica"},{"issue":"3","key":"1189_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ejh.14222","volume":"113","author":"M Roussel","year":"2024","unstructured":"Roussel M, Texier N, Nael V, Bitetti J, Paka P, Kerbouche N, et al. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: the ALFA study. Eur J Haematol. 2024;113(3):310\u201320.","journal-title":"Eur J Haematol"},{"issue":"18","key":"1189_CR33","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"issue":"9","key":"1189_CR34","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","volume":"26","author":"KA Frerichs","year":"2020","unstructured":"Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, et al. Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. Clin Cancer Res. 2020;26(9):2203\u201315.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1189_CR35","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1021\/jacs.5b01876","volume":"137","author":"NS Ramadoss","year":"2015","unstructured":"Ramadoss NS, Schulman AD, Choi SH, Rodgers DT, Kazane SA, Kim CH, et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J Am Chem Soc. 2015;137(16):5288\u201391.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"1189_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396\u2013410.","journal-title":"Cancer Cell"},{"issue":"5","key":"1189_CR37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5(5):1291\u2013304.","journal-title":"Blood Adv"},{"issue":"4","key":"1189_CR38","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711-25.e6.","journal-title":"Cancer Cell"},{"issue":"6","key":"1189_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"10301","key":"1189_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"key":"1189_CR41","doi-asserted-by":"crossref","unstructured":"Oriol A, Popat R, Garfall A, Nooka A, van de Donk Niels WCJ, Moreau P, et al. Long-term follow-up from the phase 1\/2 majestec-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. Presented at EHA. 2024; p 942","DOI":"10.1016\/S2152-2650(24)01970-0"},{"issue":"2","key":"1189_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38(2):365\u201371.","journal-title":"Leukemia"},{"issue":"1","key":"1189_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14(1):35.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1189_CR44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","volume":"30","author":"A Jourdes","year":"2024","unstructured":"Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, et al. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. Clin Microbiol Infect. 2024;30(6):764\u201371.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1189_CR45","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3324\/haematol.2024.286118","volume":"110","author":"A Perrot","year":"2025","unstructured":"Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, et al. Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program. Haematologica. 2025;110(4):990\u20134.","journal-title":"Haematologica"},{"issue":"7","key":"1189_CR46","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","volume":"8","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, et al. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naive multiple myeloma. Blood Adv. 2024;8(7):1600\u201311.","journal-title":"Blood Adv"},{"issue":"1","key":"1189_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01297-7","volume":"15","author":"O Pasvolsky","year":"2025","unstructured":"Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, et al. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. multiple myeloma immunotherapy consortium. Blood Cancer J. 2025;15(1):92.","journal-title":"Blood Cancer J"},{"key":"1189_CR48","doi-asserted-by":"crossref","unstructured":"Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, et al. Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025:OF1\u201311.","DOI":"10.1158\/2643-3230.30516448"},{"issue":"1","key":"1189_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01314-9","volume":"15","author":"D Dima","year":"2025","unstructured":"Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, et al. Outcomes of teclistamab in patients with relapsed\/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025;15(1):111.","journal-title":"Blood Cancer J"},{"key":"1189_CR50","doi-asserted-by":"publisher","unstructured":"Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, et al. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025017597.","DOI":"10.1182\/bloodadvances.2025017597"},{"issue":"5","key":"1189_CR51","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion Study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther. 2023;40(5):2412\u201325.","journal-title":"Adv Ther"},{"issue":"5","key":"1189_CR52","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","volume":"23","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, et al. Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(5):385\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1189_CR53","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0186","volume":"12","author":"A Krishnan","year":"2023","unstructured":"Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, et al. Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma. J Comp Eff Res. 2023;12(6):e220186.","journal-title":"J Comp Eff Res"},{"issue":"10","key":"1189_CR54","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136.","journal-title":"Nat Med"},{"issue":"9","key":"1189_CR55","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"issue":"7","key":"1189_CR56","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere. 2024;8(7):e136.","journal-title":"Hemasphere."},{"key":"1189_CR57","doi-asserted-by":"crossref","unstructured":"Manier S, Lesokhin A, Mohty M, Niesvizky R, Maisel C, Arnulf B, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from magnetismm studies. Presented at EHA. 2023. P870.","DOI":"10.1097\/01.HS9.0000970384.26808.c7"},{"issue":"1","key":"1189_CR58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","volume":"14","author":"F Malard","year":"2024","unstructured":"Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, et al. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 2024;14(1):219.","journal-title":"Blood Cancer J"},{"issue":"17","key":"1189_CR59","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2023-0995","volume":"20","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, et al. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncol. 2024;20(17):1175\u201389.","journal-title":"Future Oncol"},{"issue":"2","key":"1189_CR60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","volume":"40","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma. Curr Med Res Opin. 2024;40(2):199\u2013207.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1189_CR61","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0236","volume":"14","author":"I Mol","year":"2025","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. Elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma: an updated matching-adjusted indirect comparison. J Comp Eff Res. 2025;14(5):e240236.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"1189_CR62","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65(5):660\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1189_CR63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-025-01217-9","volume":"15","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SMA, Vekeman F, et al. An updated indirect comparison of elranatamab versus a real-world external control arm in triple-class refractory multiple myeloma. Blood Lymphat Cancer. 2025;15:11\u201320.","journal-title":"Blood Lymphat Cancer."},{"issue":"1","key":"1189_CR64","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1186\/s12885-025-14624-9","volume":"25","author":"C Tsang","year":"2025","unstructured":"Tsang C, O\u2019Reilly JE, Carpenter L, Duffield C, Tunaru F, Wallis J, et al. Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma. BMC Cancer. 2025;25(1):1219.","journal-title":"BMC Cancer"},{"issue":"22","key":"1189_CR65","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1189_CR66","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2025.06.014","volume":"25","author":"HC Lee","year":"2025","unstructured":"Lee HC, Bumma N, Richter J, Zonder JA, Hoffman JE, Zhou ZY, et al. Indirect comparison of linvoseltamab versus teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"1189_CR67","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543\u201354.","journal-title":"Leukemia"},{"issue":"1","key":"1189_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-025-01254-4","volume":"15","author":"F Chunara","year":"2025","unstructured":"Chunara F, Lugo C, Osinski K, Shah MR, Shah N, Kent J, et al. Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. Blood Cancer J. 2025;15(1):61.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1189_CR69","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","volume":"104","author":"M Stork","year":"2025","unstructured":"Stork M, Radocha J, Mihalyova J, Spicka I, Pika T, Jungova A, et al. De-escalated teclistamab dosing in relapsed\/refractory multiple myeloma: Czech Myeloma Group real-world evidence analysis. Ann Hematol. 2025;104(8):4141\u20137.","journal-title":"Ann Hematol"},{"issue":"10","key":"1189_CR70","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104\u201318.","journal-title":"Blood"},{"issue":"1","key":"1189_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","volume":"14","author":"R Chakraborty","year":"2024","unstructured":"Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, et al. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma. Blood Cancer J. 2024;14(1):137.","journal-title":"Blood Cancer J"},{"key":"1189_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03406-8","volume-title":"Sustained remission after limited-duration of bispecific antibody therapy in patients with relapsed\/refractory multiple myeloma","author":"G Vega","year":"2025","unstructured":"Vega G, Morillo D, Riedhammer C, Bag A, Julian KL, Tovar N, et al. Sustained remission after limited-duration of bispecific antibody therapy in patients with relapsed\/refractory multiple myeloma. Toronto: International Myeloma Society; 2025."},{"issue":"31","key":"1189_CR73","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D'Souza","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022;40(31):3576\u201386.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1189_CR74","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"10297","key":"1189_CR75","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"5","key":"1189_CR76","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018;29(5):585\u2013601.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"1189_CR77","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"1189_CR78","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"17","key":"1189_CR79","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","volume":"8","author":"NM Kalariya","year":"2024","unstructured":"Kalariya NM, Hildebrandt MAT, Hansen Dk, Sidana S, Khouri J, Ferreri CJ, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024;8(17):4679\u201388.","journal-title":"Blood Adv"},{"issue":"1","key":"1189_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. Hemasphere. 2025;9(1):e70070.","journal-title":"Hemasphere."},{"issue":"13","key":"1189_CR81","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(13):1597\u2013609.","journal-title":"J Clin Oncol"},{"key":"1189_CR82","doi-asserted-by":"crossref","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2024.","DOI":"10.1136\/jitc-2024-009220"},{"key":"1189_CR83","doi-asserted-by":"crossref","unstructured":"Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, et al. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): a real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024;205(3):990\u20138.","DOI":"10.1111\/bjh.19505"},{"issue":"15","key":"1189_CR84","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","volume":"8","author":"M Mejia Saldarriaga","year":"2024","unstructured":"Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8(15):3859\u201369.","journal-title":"Blood Adv"},{"issue":"8","key":"1189_CR85","doi-asserted-by":"publisher","first-page":"790.e1","DOI":"10.1016\/j.jtct.2024.05.025","volume":"30","author":"J Khouri","year":"2024","unstructured":"Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, et al. Absolute lymphocyte count and outcomes of multiple myeloma patients treated with idecabtagene vicleucel: the US Myeloma Immunotherapy Consortium real-world experience. Transplant Cell Ther. 2024;30(8):790.e1-16.","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"1189_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):63.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1189_CR87","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","volume":"109","author":"S Sidana","year":"2024","unstructured":"Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica. 2024;109(3):777\u201386.","journal-title":"Haematologica"},{"issue":"9","key":"1189_CR88","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","volume":"30","author":"W Wesson","year":"2024","unstructured":"Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, et al. Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma. Transplant Cell Ther. 2024;30(9):876\u201384.","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"1189_CR89","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1189_CR90","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/bloodadvances.2024014970","volume":"9","author":"OS Akhtar","year":"2025","unstructured":"Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025;9(7):1587\u201392.","journal-title":"Blood Adv"},{"issue":"14","key":"1189_CR91","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2025028330","volume":"146","author":"M Merz","year":"2025","unstructured":"Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, et al. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood. 2025;146(14):1677\u201386.","journal-title":"Blood"},{"issue":"2","key":"1189_CR92","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2024026216","volume":"146","author":"S Sidana","year":"2025","unstructured":"Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma. Blood. 2025;146(2):167\u201377.","journal-title":"Blood"},{"issue":"1","key":"1189_CR93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1189_CR94","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"1189_CR95","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1189_CR96","doi-asserted-by":"crossref","unstructured":"Munshi N, Martin T, Usmani SZ, Berdeja J, Jakubowiak A, Agha M, et al. S202: cartitude-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. HemaSphere. 2023.","DOI":"10.1097\/01.HS9.0000967720.61024.68"},{"issue":"25","key":"1189_CR97","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(25):2766\u201371.","journal-title":"J Clin Oncol"},{"key":"1189_CR98","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"1189_CR99","doi-asserted-by":"crossref","unstructured":"Mateos MV, San-Miguel J, Dhakal B. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update. In: 21st International Myeloma Society (IMS) annual meeting, 2024, Rio de Janeiro.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"issue":"1","key":"1189_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397.","journal-title":"Blood"},{"issue":"10","key":"1189_CR101","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1007\/s12325-025-03308-2","volume":"42","author":"C Touzeau","year":"2025","unstructured":"Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-4 versus real-world physician\u2019s choice of therapy from the Flatiron Registry in lenalidomide-refractory multiple myeloma. Adv Ther. 2025;42(10):5023\u201341.","journal-title":"Adv Ther"},{"issue":"9","key":"1189_CR102","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1007\/s12325-025-03278-5","volume":"42","author":"R Fonseca","year":"2025","unstructured":"Fonseca R, Diels J, Ghilotti F, Mendes J, Van Hoorenbeeck S, Lee S, et al. Survival outcomes with cilta-cel versus conventional treatment regimens for patients with lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Adv Ther. 2025;42(9):4418\u201331.","journal-title":"Adv Ther"},{"issue":"7","key":"1189_CR103","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s12325-025-03205-8","volume":"42","author":"N Puig","year":"2025","unstructured":"Puig N, Diels J, van Sanden S, Mendes J, Burnett H, Cichewicz A, et al. Comparative efficacy of ciltacabtagene autoleucel versus standard-of-care treatments for patients with previously treated relapsed or refractory multiple myeloma: a matching-adjusted indirect comparison. Adv Ther. 2025;42(7):3223\u20139.","journal-title":"Adv Ther"},{"issue":"1","key":"1189_CR104","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM, Roccia T, Jackson CC, Deraedt W, et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2023;39(1):81\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1189_CR105","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato JM, Edwards JP, Zaritskaya L, Witter AR, Gupta A, LaFleur DW, et al. Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain. Mol Cancer Ther. 2022;21(7):1171\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"Suppl. 1","key":"1189_CR106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201080","volume":"144","author":"MR Bishop","year":"2024","unstructured":"Bishop MR, Rosenblatt J, Dhakal B, Raje N, Cook D, Gaballa MR, et al. Phase 1 study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma (RRMM): efficacy and safety with 34-month median follow-up. Blood. 2024;144(Suppl. 1):4825.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1189_CR107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198499","volume":"144","author":"CL Freeman","year":"2024","unstructured":"Freeman CL, Dhakal B, Kaur G, Maziarz RT, Callander N, Sperling AS, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 Trial. Blood. 2024;144(Suppl. 1):1031.","journal-title":"Blood"},{"issue":"3","key":"1189_CR108","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","volume":"1518","author":"H Brauner-Osborne","year":"2001","unstructured":"Brauner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O\u2019Hara P. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001;1518(3):237\u201348.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1189_CR109","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Investig Dermatol. 2004;122(3):565\u201373.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"1189_CR110","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196\u2013215.","journal-title":"Blood Adv"},{"issue":"9","key":"1189_CR111","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, Kochi Y, Nakai W, Mizuno H, Baba T, Habu K, et al. Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"1189_CR112","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood.V122.21.3099.3099","volume":"122","author":"SU Venkateshaiah","year":"2013","unstructured":"Venkateshaiah SU, Bam R, Li X, Khan S, Ling W, Randal S, et al. GPRC5D is a cell surface plasma cell marker whose expression is high in myeloma cells and reduced following coculture with osteoclasts. Blood. 2013;122(21):3099.","journal-title":"Blood"},{"issue":"15","key":"1189_CR113","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","volume":"135","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Edavettal S, Mendonca M, Li Y, Tornetta M, Babich A, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D \u00d7 CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u201343.","journal-title":"Blood"},{"key":"1189_CR114","doi-asserted-by":"publisher","first-page":"s91","DOI":"10.1016\/S2152-2650(21)02229-1","volume":"21","author":"R Goldsmith","year":"2021","unstructured":"Goldsmith R, Cornax I, Ma JY, Yao X, Peng P, Carreira V. P-095: normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissues. Clin Lymphoma Myeloma Leukemia. 2021;21:s91.","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"issue":"9","key":"1189_CR115","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Investig. 2012;42(9):953\u201360.","journal-title":"Eur J Clin Investig"},{"issue":"485","key":"1189_CR116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):7746.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1189_CR117","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","volume":"18","author":"Y Cohen","year":"2013","unstructured":"Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 2013;18(6):348\u201351.","journal-title":"Hematology"},{"issue":"24","key":"1189_CR118","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1189_CR119","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 2025;12(4):e269\u201381.","journal-title":"Lancet Haematol."},{"issue":"4","key":"1189_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70114","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, et al. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. Hemasphere. 2025;9(4):e70114.","journal-title":"Hemasphere"},{"key":"1189_CR121","doi-asserted-by":"crossref","unstructured":"Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, et al. Sequential targeting in multiple myeloma: Talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T cell therapy. Blood. 2025;146(17):2063\u201372.","DOI":"10.1182\/blood.2025029773"},{"issue":"4","key":"1189_CR122","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jha2.971","volume":"5","author":"S Naqvi","year":"2024","unstructured":"Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, et al. Weight loss and dysgeusia in relapsed\/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024;5(4):789\u201392.","journal-title":"EJHaem"},{"issue":"10","key":"1189_CR123","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","volume":"40","author":"C Schinke","year":"2024","unstructured":"Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, et al. Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin. 2024;40(10):1705\u201311.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1189_CR124","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, et al. Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-93.e14.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1189_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2024.151712","volume":"40","author":"D Catamero","year":"2024","unstructured":"Catamero D, Ray C, Purcell K, Leahey S, Esler E, Rogers S, et al. Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma. Semin Oncol Nurs. 2024;40(5):151712.","journal-title":"Semin Oncol Nurs"},{"issue":"6","key":"1189_CR126","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","volume":"19","author":"D Pan","year":"2024","unstructured":"Pan D, Richter R. Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma. Curr Hematol Malig Rep. 2024;19(6):237\u201345.","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl. 1","key":"1189_CR127","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"S Bal","year":"2024","unstructured":"Bal S, Anderson LD, Nadeem O, Berdeja JG, Rossi A, Gregory T, et al. Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed\/refractory (RR) multiple myeloma (MM). Blood. 2024;144(Suppl. 1):922.","journal-title":"Blood"},{"issue":"2","key":"1189_CR128","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392(2):138\u201349.","journal-title":"N Engl J Med"},{"key":"1189_CR129","doi-asserted-by":"publisher","unstructured":"Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, et al. Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025030027","DOI":"10.1182\/blood.2025030027"},{"key":"1189_CR130","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Vega G, Perrot A, Anguille S, Oriol A, Minnema M, et al. First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results. J Clin Oncol. 2025;43(16_Suppl.):7505.","DOI":"10.1200\/JCO.2025.43.16_suppl.7505"},{"key":"1189_CR131","doi-asserted-by":"crossref","unstructured":"Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019.","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"1189_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101218","volume":"66","author":"CC Mo","year":"2024","unstructured":"Mo CC, Richardson E, Calabretta E, Corrado F, Kocoglu MH, Baron RM, et al. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide. Blood Rev. 2024;66:101218.","journal-title":"Blood Rev"},{"issue":"1","key":"1189_CR133","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Xu J, Dai Y, Jin S, Sun Y, Li J, et al. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat Commun. 2024;15(1):360.","journal-title":"Nat Commun"},{"key":"1189_CR134","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno Jn, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"issue":"5","key":"1189_CR135","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, Gallego Perez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25(5):e205\u201316.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1189_CR136","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255\u201369.","journal-title":"Lancet Oncol"},{"key":"1189_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272","volume":"71","author":"S Pagliuca","year":"2025","unstructured":"Pagliuca S, Malard F, Mooyaart JE, Daskalakis M, Gabellier L, Yakoub-Agha I, et al. The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Rev. 2025;71:101272.","journal-title":"Blood Rev"},{"issue":"9","key":"1189_CR138","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","volume":"32","author":"DN Biery","year":"2024","unstructured":"Biery DN, Turicek DP, Diorio C, Schroeder BA, Shah NN. Need for standardization of cytokine profiling in CAR T cell therapy. Mol Ther. 2024;32(9):2979\u201383.","journal-title":"Mol Ther"},{"issue":"12","key":"1189_CR139","doi-asserted-by":"publisher","first-page":"989-999","DOI":"10.1016\/j.jtct.2025.08.015","volume":"31","author":"K Sweiss","year":"2025","unstructured":"Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, et al. Fludarabine lymphodepletion exposure is associated with toxicities after idecabtagene-vicleucel in relapsed\/refractory multiple myeloma: real-world experience from the US myeloma immunotherapy consortium. Transplant Cell Ther. 2025.","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"1189_CR140","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374\u201387.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1189_CR141","first-page":"3557","volume":"109","author":"O Penack","year":"2024","unstructured":"Penack O, Peczynski C, Boreland W, Wolff D, Moiseev I, Schoemans H, et al. Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation. Haematologica. 2024;109(11):3557\u201365.","journal-title":"Haematologica"},{"issue":"23","key":"1189_CR142","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","volume":"5","author":"VE Kennedy","year":"2021","unstructured":"Kennedy VE, Wong C, Huang CY, Thiruvengadam SK, Wolf J, Martin TG, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344\u20138.","journal-title":"Blood Adv"},{"issue":"7","key":"1189_CR143","doi-asserted-by":"publisher","first-page":"438e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29(7):438e1-516.","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"1189_CR144","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"1189_CR145","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood.2024025679","volume":"144","author":"X Deschenes-Simard","year":"2024","unstructured":"Deschenes-Simard X, Santomasso BD, Dahi PB. Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood. 2024;144(20):2083\u201394.","journal-title":"Blood"},{"key":"1189_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1108297","volume":"14","author":"V Genoud","year":"2023","unstructured":"Genoud V, Migliorini D. Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front Neurol. 2023;14:1108297.","journal-title":"Front Neurol"},{"issue":"1","key":"1189_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16(1):88.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1189_CR148","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","volume":"8","author":"M Mauget","year":"2024","unstructured":"Mauget M, Lemercier S, Quelven Q, Maamar A, Lhomme F, De Guibert S, et al. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity. Blood Adv. 2024;8(10):2491\u20138.","journal-title":"Blood Adv"},{"issue":"3","key":"1189_CR149","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/bjh.19270","volume":"204","author":"GM Asioli","year":"2024","unstructured":"Asioli GM, Castioni CA, Zinzani PL, Casadio MC, Pierucci E, Casadei B, et al. Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: not all is lost! Br J Haematol. 2024;204(3):1109\u201313.","journal-title":"Br J Haematol"},{"issue":"2","key":"1189_CR150","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, van de Donk N, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1189_CR151","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-025-60980-2","volume":"16","author":"D Atanackovic","year":"2025","unstructured":"Atanackovic D, Luetkens T, Schneider D, Hu P, Wang X, Shetty AC, et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat Commun. 2025;16(1):6154.","journal-title":"Nat Commun"},{"issue":"14","key":"1189_CR152","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","volume":"9","author":"K Kelly","year":"2025","unstructured":"Kelly K, Cooperrider JH, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025;9(14):3613\u20136.","journal-title":"Blood Adv"},{"issue":"14","key":"1189_CR153","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PC, Raje N, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142(14):1243\u20138.","journal-title":"Blood"},{"issue":"23","key":"1189_CR154","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE, Leick MB, Chowdhury MR, King M, et al. Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood. 2025;145(23):2788\u201393.","journal-title":"Blood"},{"key":"1189_CR155","doi-asserted-by":"publisher","first-page":"1444010","DOI":"10.3389\/fimmu.2024.1444010","volume":"15","author":"R Aliakbar","year":"2024","unstructured":"Aliakbar R, Manouvakhova O, Wong C, Htut M, Pulst-Korenberg J, Janakiram M, et al. Case report: treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen. Front Immunol. 2024;15:1444010.","journal-title":"Front Immunol"},{"issue":"3","key":"1189_CR156","doi-asserted-by":"publisher","first-page":"146","DOI":"10.14740\/jh2046","volume":"14","author":"B Wirk","year":"2025","unstructured":"Wirk B, Lim J. Ruxolitinib is an effective therapy for ciltacabtagene autoleucel-associated Parkinsonism in multiple myeloma. J Hematol. 2025;14(3):146\u201351.","journal-title":"J Hematol"},{"key":"1189_CR157","unstructured":"EMA. European public Assessment report: Abecma."},{"key":"1189_CR158","unstructured":"FDA. Abecma (idecabtagene vicleucel). Vaccines Blood Biologics [06-12-2024 23-01-2025]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel. Accessed 13 Dec 2025."},{"issue":"1","key":"1189_CR159","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-024-01023-9","volume":"14","author":"Z Gong","year":"2024","unstructured":"Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, et al. Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood Cancer J. 2024;14(1):36.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1189_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.131","volume":"8","author":"A Couturier","year":"2024","unstructured":"Couturier A, Escoffre M, Leh F, Villoteau AS, Palard X, Le Jeune F, et al. Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel. Hemasphere. 2024;8(7):e131.","journal-title":"Hemasphere"},{"issue":"2","key":"1189_CR161","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/j.jtct.2025.01.330","volume":"31","author":"J Turner","year":"2025","unstructured":"Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma. Transplant Cell Ther. 2025;31(2):S215\u20136.","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"1189_CR162","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant Cell Ther. 2025;31(2):71.e1-14.","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"1189_CR163","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3324\/haematol.2023.283296","volume":"109","author":"YK Kathari","year":"2024","unstructured":"Kathari YK, Ahmad H, Kallen ME, Koka R, Omili D, Iraguha T, et al. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica. 2024;109(2):682\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"1189_CR164","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/19418744231167290","volume":"13","author":"N Patrick","year":"2023","unstructured":"Patrick N, Bahlis N, Peters S. Chimeric antigen receptor-T cell mediated bilateral facial nerve palsy: a case report. Neurohospitalist. 2023;13(3):308\u201311.","journal-title":"Neurohospitalist"},{"issue":"10","key":"1189_CR165","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377.","journal-title":"Blood"},{"issue":"6","key":"1189_CR166","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11(6):e459\u201370.","journal-title":"Lancet Haematol"},{"issue":"9","key":"1189_CR167","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","volume":"29","author":"JA Davis","year":"2023","unstructured":"Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther. 2023;29(9):567\u201371.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"1189_CR168","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024;30(3):308.e1-13.","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"1189_CR169","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313.","journal-title":"Haematologica"},{"issue":"1","key":"1189_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08451-x","volume":"21","author":"N Balmaceda","year":"2021","unstructured":"Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21(1):730.","journal-title":"BMC Cancer"},{"key":"1189_CR171","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","volume":"16","author":"E Backhaus","year":"2016","unstructured":"Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16:367.","journal-title":"BMC Infect Dis"},{"key":"1189_CR172","doi-asserted-by":"crossref","unstructured":"Blimark CH, Carlson K, Day C, Einarsdottir S, Juliusson G, Karma M, et al. Risk of infections in multiple myeloma A populationbased study on 8,672 multiple myeloma patients diagnosed 2008\u20132021 from the Swedish Myeloma Registry. Haematologica. 2025;110(1):163\u201372.","DOI":"10.3324\/haematol.2024.285645"},{"issue":"6","key":"1189_CR173","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2011.054015","volume":"97","author":"SY Kristinsson","year":"2012","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854\u20138.","journal-title":"Haematologica"},{"issue":"2","key":"1189_CR174","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0609.1998.tb01075.x","volume":"61","author":"H Gregersen","year":"1998","unstructured":"Gregersen H, Madsen KM, Sorensen HT, Schonheyder HS, Ibsen JS, Dahlerup JF. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol. 1998;61(2):140\u20134.","journal-title":"Eur J Haematol"},{"issue":"36","key":"1189_CR175","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219\u201326.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1189_CR176","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1002\/ajh.23932","volume":"90","author":"MO Holmstrom","year":"2015","unstructured":"Holmstrom MO, Gimsing P, Abildgaard N, Andersen NF, Helleberg C, Clausen NA, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90(4):E73\u20134.","journal-title":"Am J Hematol"},{"issue":"10","key":"1189_CR177","doi-asserted-by":"publisher","first-page":"E611","DOI":"10.1002\/ajh.24857","volume":"92","author":"K Thidemann Andersen","year":"2017","unstructured":"Thidemann Andersen K, Klausen T, Abildgaard N, Klarskov Andersen M, Frost Andersen N, Christian Frolund U, et al. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous stem cell transplantation: a study based on the nationwide Danish Multiple Myeloma Registry. Am J Hematol. 2017;92(10):E611\u20134.","journal-title":"Am J Hematol"},{"issue":"2","key":"1189_CR178","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143\u201361.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1189_CR179","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","volume":"35","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31\u201344.","journal-title":"Leukemia"},{"issue":"6","key":"1189_CR180","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130(6):886\u2013900.","journal-title":"Cancer"},{"issue":"19","key":"1189_CR181","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898\u2013903.","journal-title":"Blood Adv"},{"issue":"13","key":"1189_CR182","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"F Mazahreh","year":"2023","unstructured":"Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7(13):3069\u201374.","journal-title":"Blood Adv"},{"issue":"11","key":"1189_CR183","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","volume":"108","author":"B Palmen","year":"2023","unstructured":"Palmen B, Hari P, D\u2019Souza A, Abid MB. Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen. Haematologica. 2023;108(11):3186\u201390.","journal-title":"Haematologica"},{"issue":"1","key":"1189_CR184","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","volume":"14","author":"K Nath","year":"2024","unstructured":"Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, et al. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14(1):88.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1189_CR185","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38961","volume":"5","author":"LR Hammons","year":"2022","unstructured":"Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D\u2019Souza A, et al. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open. 2022;5(10):e2238961.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1189_CR186","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4(6):440\u201351.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"1189_CR187","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024;8(1):194\u2013206.","journal-title":"Blood Adv"},{"issue":"18","key":"1189_CR188","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","volume":"7","author":"JS Little","year":"2023","unstructured":"Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, et al. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023;7(18):5485\u201395.","journal-title":"Blood Adv"},{"issue":"24","key":"1189_CR189","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6(24):6109\u201319.","journal-title":"Blood Adv"},{"issue":"10","key":"1189_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00563-8","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Mao X, Que Y, Xu M, Cheng Y, Huang L, et al. Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. Blood Cancer J. 2021;11(10):168.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1189_CR191","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-023-01960-2","volume":"58","author":"S Fu","year":"2023","unstructured":"Fu S, Zhang Q, Jing R, Zu C, Ni F, Lv Y, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transplant. 2023;58(6):701\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1189_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1189_CR193","volume":"32","author":"A Laheij","year":"2023","unstructured":"Laheij A, van de Donk N. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer. 2023;32(1):20.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1189_CR194","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs. 2014;32(6):1246\u201357.","journal-title":"Investig New Drugs"},{"issue":"11","key":"1189_CR195","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.3324\/haematol.2024.285821","volume":"109","author":"U Munawar","year":"2024","unstructured":"Munawar U, Theuersbacher J, Steinhardt MJ, Zhou X, Han S, Nerreter S, et al. Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. Haematologica. 2024;109(11):3670\u201380.","journal-title":"Haematologica"},{"issue":"5","key":"1189_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00494-4","volume":"11","author":"S Lonial","year":"2021","unstructured":"Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11(5):103.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1189_CR197","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/ajh.70015","volume":"100","author":"E Terpos","year":"2025","unstructured":"Terpos E, Trudel S, Mateos MV, Alejandre N, Colby K, Dimopoulos MA, et al. Practical guidance on clinical management of belantamab mafodotin-associated ocular events. Am J Hematol. 2025;100(10):1839\u201350.","journal-title":"Am J Hematol"},{"key":"1189_CR198","doi-asserted-by":"crossref","unstructured":"Liang X, Luo B, Lin B, Liu D, Guo J, Lu W, et al. Characteristics of second primary malignancies following bispecific antibodies therapy. J Immunother Cancer. 2025.","DOI":"10.1136\/jitc-2024-011200"},{"issue":"20","key":"1189_CR199","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30(20):4690\u2013700.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1189_CR200","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","volume":"31","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, et al. Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy. Clin Cancer Res. 2025;31(20):4333\u201344.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1189_CR201","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17(1):23.","journal-title":"J Hematol Oncol"},{"key":"1189_CR202","doi-asserted-by":"crossref","unstructured":"Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N Engl J Med. 2025;392(7):677\u201385.","DOI":"10.1056\/NEJMoa2309728"},{"issue":"7","key":"1189_CR203","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.clml.2024.03.002","volume":"24","author":"C Nagarajan","year":"2024","unstructured":"Nagarajan C, Eu Jo MW, Martin 3rdTG. BCMA directed bispecific antibody induced tumor flare in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24(7):488\u201390.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1189_CR204","first-page":"2368","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M, Janakiram M, Kalbi D, Verma A, et al. Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica. 2024;109(7):2368\u201371.","journal-title":"Haematologica"},{"issue":"5","key":"1189_CR205","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1097\/RLU.0000000000004588","volume":"48","author":"B Jamet","year":"2023","unstructured":"Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodere F, Touzeau C. 2-[18F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. Clin Nucl Med. 2023;48(5):e230\u20131.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1189_CR206","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Moran-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14(1):180.","journal-title":"Blood Cancer J"},{"key":"1189_CR207","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S2152-2650(24)01911-6","volume":"24","author":"N Bar","year":"2024","unstructured":"Bar N, Yee A, Dhakal B, Frigault M, Richard S, Cohen A, et al. P-008 A Rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; insights from a multicenter case series. Clin Lymphoma Myeloma Leukemia. 2024;24:S44\u20135.","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"issue":"2","key":"1189_CR208","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1016\/j.jtct.2025.01.357","volume":"31","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Chhabra S, Corraes ADMS, Parrondo RD, Gertz M, Hwa L, et al. Risk Factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Transplant Cell Ther. 2025;31(2):S234\u20135.","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"1189_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28266-z","volume":"13","author":"M Merz","year":"2022","unstructured":"Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N, et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun. 2022;13(1):807.","journal-title":"Nat Commun"},{"issue":"1","key":"1189_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13(1):4517.","journal-title":"Nat Commun"},{"issue":"1","key":"1189_CR211","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, Mallm JP, Steiger S, Poos AM, Awwad MHS, Giesen N, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960.","journal-title":"Nat Commun"},{"issue":"1","key":"1189_CR212","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"issue":"12","key":"1189_CR213","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825\u201334.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1189_CR214","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"N van de Donk","year":"2024","unstructured":"van de Donk N, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11(9):e693-707.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1189_CR215","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302\u201318.","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"1189_CR216","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Rasche L, Kortum KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023;108(4):958\u201368.","journal-title":"Haematologica"},{"issue":"15","key":"1189_CR217","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145(15):1645\u201357.","journal-title":"Blood"},{"issue":"3","key":"1189_CR218","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/bjh.70012","volume":"207","author":"N Martin","year":"2025","unstructured":"Martin N, Thompson E, Stong N, Xu Y, Finney O, Rytlewski J, et al. Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. Br J Haematol. 2025;207(3):1019\u201328.","journal-title":"Br J Haematol"},{"issue":"4","key":"1189_CR219","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2023;7(4):644\u20138.","journal-title":"Blood Adv"},{"issue":"25","key":"1189_CR220","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee H, Durante M, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 2024;144(25):2637\u201351.","journal-title":"Blood"},{"issue":"3","key":"1189_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12(3):45.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1189_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01330-9","volume":"15","author":"MJ Steinhardt","year":"2025","unstructured":"Steinhardt MJ, Schaefers C, Leypoldt LB, Blau IW, Harzer M, Zhou X, et al. Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement. Blood Cancer J. 2025;15(1):126.","journal-title":"Blood Cancer J"},{"key":"1189_CR223","doi-asserted-by":"crossref","unstructured":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, et al. Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica. 2025;110(12):3065\u201377.","DOI":"10.3324\/haematol.2025.287985"},{"issue":"14","key":"1189_CR224","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(14):1665\u201375.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1189_CR225","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70139","volume":"6","author":"T Richardson","year":"2025","unstructured":"Richardson T, Tharmaseelan H, Kobbe G, Baermann BN, Holderried TAW, Schmitz F, et al. Early free light-chain suppression as a prognostic marker in relapsed and refractory myeloma patients treated with BCMA-directed CAR-T cells. EJHaem. 2025;6(5):e70139.","journal-title":"EJHaem"},{"issue":"21","key":"1189_CR226","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","volume":"7","author":"MK Samur","year":"2023","unstructured":"Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7(21):6599\u2013603.","journal-title":"Blood Adv"},{"issue":"19","key":"1189_CR227","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"MS Truger","year":"2021","unstructured":"Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Adv. 2021;5(19):3794\u20138.","journal-title":"Blood Adv"},{"issue":"4","key":"1189_CR228","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"1189_CR229","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"2","key":"1189_CR230","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood.2024025231","volume":"145","author":"DG Coffey","year":"2025","unstructured":"Coffey DG, Ataca Atilla P, Atilla E, Landgren O, Cowan AJ, Simon S, et al. Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy. Blood. 2025;145(2):220\u201333.","journal-title":"Blood"},{"issue":"6","key":"1189_CR231","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144(6):615\u201328.","journal-title":"Blood"},{"issue":"1","key":"1189_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868.","journal-title":"Nat Commun"},{"issue":"4","key":"1189_CR233","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024;144(4):402\u20137.","journal-title":"Blood"},{"issue":"11","key":"1189_CR234","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4(11):1536\u201343.","journal-title":"Nat Cancer"},{"issue":"19","key":"1189_CR235","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585\u201397.","journal-title":"Blood"},{"issue":"9","key":"1189_CR236","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394.","journal-title":"Nat Med"},{"issue":"2","key":"1189_CR237","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","volume":"38","author":"L Fischer","year":"2024","unstructured":"Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38(2):372\u201382.","journal-title":"Leukemia"},{"issue":"2","key":"1189_CR238","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","volume":"30","author":"AK Mishra","year":"2024","unstructured":"Mishra AK, Schmidt TM, Martell EB, Chen AS, Dogru RE, Hematti P, et al. PD1(+)TIGIT(+)2B4(+)KLRG1(+) cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2024;30(2):191\u2013202.","journal-title":"Transplant Cell Ther"},{"issue":"13","key":"1189_CR239","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8(13):3562\u201375.","journal-title":"Blood Adv"},{"issue":"6","key":"1189_CR240","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1189_CR241","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3(6):490\u2013501.","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"1189_CR242","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/jha2.479","volume":"3","author":"A Abecassis","year":"2022","unstructured":"Abecassis A, Roders N, Fayon M, Choisy C, Nelson E, Harel S, et al. CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment. EJHaem. 2022;3(3):970\u20134.","journal-title":"EJHaem"},{"issue":"14","key":"1189_CR243","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30(14):3006\u201322.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1189_CR244","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12(1):44.","journal-title":"Exp Hematol Oncol"},{"key":"1189_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1278749","volume":"14","author":"Y Xia","year":"2023","unstructured":"Xia Y, Zhao Q, Shen X, Jin Y, Wang J, Zhu J, et al. Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma. Front Immunol. 2023;14:1278749.","journal-title":"Front Immunol"},{"issue":"9","key":"1189_CR246","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat Cancer. 2024;5(9):1318\u201333.","journal-title":"Nat Cancer"},{"key":"1189_CR247","doi-asserted-by":"crossref","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, et al. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Investig. 2023.","DOI":"10.1172\/JCI167629"},{"issue":"2","key":"1189_CR248","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199\u2013209.","journal-title":"Blood"},{"issue":"20","key":"1189_CR249","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","volume":"19","author":"SJ de Haart","year":"2013","unstructured":"de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res. 2013;19(20):5591\u2013601.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1189_CR250","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","volume":"27","author":"LC Holthof","year":"2021","unstructured":"Holthof LC, van der Schans JJ, Katsarou AA, Poels R, Gelderloos AT, Drent E, et al. Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis. Clin Cancer Res. 2021;27(13):3793\u2013803.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"1189_CR251","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022;139(26):3708\u201321.","journal-title":"Blood"},{"key":"1189_CR252","doi-asserted-by":"crossref","unstructured":"Shen Y, Eng JS, Fajardo F, Liang L, Li C, Collins P, et al. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. J Immunother Cancer. 2022.","DOI":"10.1136\/jitc-2021-004348"},{"issue":"Suppl. 1","key":"1189_CR253","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150923","volume":"138","author":"DT Melnekoff","year":"2021","unstructured":"Melnekoff DT, Ghodke-Puranik Y, Van Oekelen O, Aleman A, Upadhyaya B, Sebra R, et al. Single-cell profiling reveals contribution of tumor extrinsic and intrinsic factors to BCMA-targeted CAR-T cell efficacy in multiple myeloma. Blood. 2021;138(Suppl. 1):326.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1189_CR254","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1182\/blood-2024-211979","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee H, Ahn S, Poorebrahim M, Jung D, Benaoudia S, Leblay N, et al. Tumor intrinsic and antigen-independent resistance mechanisms to bispecific T cell engagers in multiple myeloma. Blood. 2024;144(Suppl. 1):1892.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1189_CR255","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206347","volume":"144","author":"D Jung","year":"2024","unstructured":"Jung D, Lee H, Chikhale S, Poorebrahim M, Ahn S, Benaoudia S, et al. NF-Kb pathway activation driven by TRAF3 loss mediates resistance to anti-BCMA T-cell based therapies in multiple myeloma. Blood. 2024;144(Suppl. 1):591.","journal-title":"Blood"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01189-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T18:02:38Z","timestamp":1771696958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01189-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":255,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01189-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Finn Segers has received travel support from Sanofi and Amgen for international symposia; he has no competing recent employment or financial interests. Michel Delforge has received fees for consultancy and honoraria from Amgen, BMS, J&J, GSK and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data are available in the public domain as publications or available abstracts, as referenced in the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FS and MD jointly designed the outline of the manuscript and reviewed the initial draft. FS made the initial draft. MD supervised the writing of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}